ACAlessandra Cavegn

Alessandra Cavegn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandra Cavegn has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Steric Stabilization of Lipid Nanoparticles by Sequence-Defined Polymer−Lipids Enhances Gene Expression

    by Evrim ÜmIt Kuzucu, Alireza Kavand, ArsénE Timothée Tergalinsky, Lorenz Herbster, David Wang, Alessandra Cavegn, Perrine Robin, JörG Huwyler, Pascal Detampel, Sandrine Gerber-Lemaire

    Polyethylene glycol (PEG) conjugated lipids are frequently used for the design of lipid nanoparticles (LNPs) in the field of gene therapy. However, conventional PEG−lipids contain a distribution of polymer chain lengths. To overcome this limitation, we have prepared a structurally defined PEG-alternative polymer-lipid platform synthesized via solid-phase peptide synthesis (SPPS), enabling precise control over polymer chain length and lipid anchor identity. A library of chain-length-defined poly(succinamide−4,7,10-trioxatridecane)n−lipid (poly(SA-TTD)n-lipid) conjugates, with hydrophilic polymer segments ranging from 923 to 2133 g/mol and varied lipid tails, was synthesized and formulated into DNA-loaded LNPs using microfluidic mixing. Systematic variation of polymer length and lipid tail structure revealed their distinct influence on NP size, colloidal stability, and DNA encapsulation efficiency. All formulations produced particles with narrow size distributions (PDI <0.2) with efficient DNA association. In vitro studies demonstrated that selected PEG-alternative LNPs significantly enhanced transfection efficiency compared to PEG2000-containing controls, achieving up to 18-fold higher transgene expression. Notably, these formulations also exhibited an approximately fourfold higher endosomal escape-associated signal. In vivo evaluation in zebrafish larvae (ZFL) further confirmed efficient systemic circulation and superior transgene expression without apparent toxicity. In summary, this work establishes a modular, sequence-defined polymer-lipid platform that provides a promising PEG alternative for LNP-mediated gene delivery.

  • Open Access

    Steric stabilization and enhanced gene expression using a polysarcosine-based lipid as an alternative to pegylation

    by Evrim Ümit Kuzucu, Serra Gürcan, David Wang, Fabian Hogenkamp, Mareike Helmdach, Devran Hüseyin Özdemir, Pascal Detampel, Alessandra Cavegn, Jörg Huwyler

    The water-soluble and biocompatible synthetic polypeptide poly(sarcosine) (pSar) can be used as an alternative to polyethylene glycol for the steric stabilization of lipid nanoparticles (LNPs). In the present study, a pSar lipid conjugate, mPep14-C14 (mPep-001), was synthesized by solid phase peptide synthesis, consisting of a monodisperse polysarcosine chain units (degree of polymerization: 14) linked via serine residue to two myristic acid chains. This lipopeptide was characterized and compare to clinically used DMG-PEG2000. pDNA-LNPs prepared with mPep14-C14 had a 2-fold increased transfection efficiency in vitro using human hepatoma HuH-7 cells. In vivo, using zebrafish larvae as a vertebrate screening model, mPep14-C14 pDNA-LNPs showed more than 6-fold higher systemic exposure, enhanced transgene expression, limited macrophage uptake, and no apparent signs of acute toxicity. Notably, mPep14-C14 induced distinct bleb-like protrusions on the LNP surface, possibly contributing to improved transfection efficiency. We conclude that mPep14-C14 combines efficient steric stabilization with superior transgene expression, demonstrating its potential as a promising PEG-free lipid alternative for pDNA-based gene delivery systems.